-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Winter came roaring without even a single hello
Winter came roaring without even a single hello
However, the pharmaceutical R&D personnel did not seem to feel the chill
On August 30, the mid-year report of listed pharmaceutical companies was disclosed.
(1) The range of per capita salary in the first half of the year is between 732 and 501,000 yuan, and the estimated annual salary is between 146,000 and 1,000,000
(1) The range of per capita salary in the first half of the year is between 732 and 501,000 yuan, and the estimated annual salary is between 146,000 and 1,000,000
(2) The average salary of BeiGene's R&D personnel in the first half of the year was 501,000, a year-on-year increase of 15%.
The average salary of BeiGene's R&D personnel in the first half of the year was 501,000, a year-on-year increase of 15%.
In the first half of 2022, PD-1 sales in China totaled 1.
Secondly, the average salary of R&D personnel in Dizhe Pharmaceuticals in the first half of the year is 358,800, and the annual salary will reach more than 700,000; Asieris Pharmaceuticals is 276,300
Dizhe Pharmaceuticals Asieris Pharmaceuticals
In the first half of the year, the average salary of R&D personnel of Junshi Biotech was 234,100 yuan, a decrease of 10%.
In the first half of 2022, the average salary of R&D personnel of Junshi Biosciences was 234,100 yuan, a decrease of 10%.
(3) In the CXO segment, the average salary of R&D personnel of Haoyuan Pharmaceuticals in the first half of the year was 167,200 yuan, a year-on-year increase of 38%; the average salary of R&D personnel of the model animal company Yaokang Biology in the first half of the year was 147,700 yuan, a sharp increase of 77% year-on-year; Chengdu Pilot and Heyuan Bio was 143,700 yuan and 128,600 yuan respectively; Sunshine Novo and Medicilon had an average salary of less than 100,000 yuan for R&D personnel in the first half of the year
(3) In the CXO segment, Haoyuan Pharmaceutical Chengdu Pioneer and Yuan Bio Sunshine Novo and Medicilon
(4) Kexing Pharmaceuticals, a leader in recombinant protein drugs in China, received an average salary of 123,700 yuan for R&D personnel in the first half of the year, a year-on-year increase of 52%, and the proportion of R&D personnel in the total number of employees increased to 15.
Sinovac Pharmaceuticals increased by 52% year-on-year
(5) The average salary of R&D personnel of ADC leader Rongchang Biotech in the first half of the year was 150,700 yuan, a year-on-year increase of 46%.
Rongchang Biology
In general, most of the pharmaceutical companies listed on the Science and Technology Innovation Board are raising salaries and expanding recruitment for R&D personnel, which is a good phenomenon
In general, most of the pharmaceutical companies listed on the Science and Technology Innovation Board are raising salaries and expanding recruitment for R&D personnel, which is a good phenomenon
.
The number and salary of R&D personnel represent the company's R&D strength and emphasis on R&D to a certain extent, and can also reflect the company's future to a certain extent
.
